5-MeO-DiBF
5-MeO-DiBF, also known as 5-methoxy-N,''N''-diisopropyl-3-benzofuran or as 1-oxa-5-MeO-DiPT, is a psychedelic drug of the benzofuran family related to the psychedelic tryptamine 5-MeO-DiPT. It is the analogue and bioisostere of 5-MeO-DiPT in which the indole nitrogen has been replaced with an oxygen atom, making it a benzofuran rather than tryptamine. The drug has been sold online as a novel designer drug starting in 2015.
The dose of 5-MeO-DiBF has been given as 10 to 40mg orally, with a light dose being 10mg, a common dose being 20mg, and a strong dose being 40mg. Its onset is said to be 45minutes and its duration is variably said to be 4 to 9hours. In addition to oral administration, the drug may also be insufflated. The effects of 5-MeO-DiBF have been reported to include psychedelic head space, tactile sensations and tingling, and increased sexual desire, among others.
Pharmacology
Pharmacodynamics
Analogues of 5-MeO-DiBF have been found to interact with serotonin receptors including the serotonin 5-HT1A and 5-HT2 receptors.
Chemistry
Analogues
Analogues of 5-MeO-DiBF include the benzofurans dimemebfe, MiPBF, 3-APB, and mebfap and the tryptamine 5-MeO-DiPT, among others.
History
5-MeO-DiBF has been sold online as a designer drug and was first definitively identified in December 2015 by a forensic laboratory in Slovenia.
Legal status
International
5-MeO-DiBF is not controlled under the United Nations 1971 Convention on Psychotropic Substances, so thus it has a legal grey area in many countries, but it's possible it could be illegal under so-called analogue acts if sold for human consumption.
Armenia
The drug is a controlled substance in Armenia as of 2022.
Canada
5-MeO-DiBF is not a controlled substance in Canada as of 2025.
5-MeO-DiBF is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.